

POST-TEST

Data + Perspectives: The Potential Role of TROP2- and CDH6-Directed Antibody-Drug Conjugates in Gynecologic Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Raludotatug deruxtecan (R-DXd) is an antibody-drug conjugate (ADC) directed against which of the following targets?**
 - Folate receptor alpha
 - CDH6**
 - HER2
 - XPO1
- What was the approximate objective response rate with R-DXd for platinum-resistant advanced ovarian cancer across all doses evaluated in the Phase II dose-optimization part of the ongoing Phase II/III REJOICE-Ovarian01 study?**
 - 15%
 - 25%
 - 50%**
 - 85%
- Which of the following adverse events is most commonly associated with R-DXd?**
 - Headache
 - Peripheral neuropathy
 - Thrombocytopenia
 - Nausea**
- Which of the following adverse events is most commonly associated with sacituzumab govitecan?**
 - Rash
 - Neutropenia**
 - Constipation
 - Hyperkalemia
- The Phase III TroFuse-005/ENGOT-EN23 study is currently evaluating sacituzumab tirumotecan versus physician's choice of chemotherapy in which of the following settings?**
 - Patients with heavily pretreated cervical cancer who have no satisfactory therapeutic alternatives
 - Patients with platinum-sensitive relapsed high-grade serous ovarian cancer
 - Patients with advanced endometrial cancer after prior platinum-based therapy and immunotherapy**
 - Patients with previously treated advanced endometrial cancer who are not eligible for platinum-based therapy